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Abstract
Objective To assess the usefulness of in-hospital mea-
surement of C-reactive protein (CRP) concentration in
comparison to well-established risk factors as a marker of
post-infarct left ventricular systolic dysfunction (LVSD) at
discharge.
Materials and methods Two hundred and four consecu-
tive patients with ST-segment-elevation myocardial
infarction (STEMI) were prospectively enrolled into the
study. CRP plasma concentrations were measured before
reperfusion, 24 h after admission and at discharge with an
ultra-sensitive latex immunoassay.
Results CRP concentration increased signiﬁcantly during
the ﬁrst 24 h of hospitalization (2.4 ± 1.9 vs. 15.7 ± 17.0
mg/L; p\0.001) and persisted elevated at discharge
(14.7 ± 14.7 mg/L), mainly in 57 patients with LVSD
(2.4 ± 1.8 vs. 25.0 ± 23.4 mg/L; p\0.001; CRP at dis-
charge 21.9 ± 18.6 mg/L). The prevalence of LVSD was
signiﬁcantly increased across increasing tertiles of CRP
concentration both at 24 h after admission (13.2 vs. 19.1
vs. 51.5 %; p\0.0001) and at discharge (14.7 vs. 23.5 vs.
45.6 %; p\0.0001). Multivariate analysis demonstrated
CRP concentration at discharge to be an independent
marker of early LVSD (odds ratio of 1.38 for a 10 mg/L
increase, 95 % conﬁdence interval 1.01–1.87; p\0.04).
Conclusion Measurement of CRP plasma concentration
at discharge may be useful as a marker of early LVSD in
patients after a ﬁrst STEMI.
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Introduction
Post-infarct left ventricular systolic dysfunction (LVSD)
has been identiﬁed as a powerful marker of poor prognosis.
Its occurrence is associated with an increased risk of car-
diac death, re-infarction and re-hospitalization [1–4].
Furthermore, half of patients diagnosed with early post-
infarct LVSD subsequently develop chronic heart failure.
The prevalence of post-infarct LVSD ranges from 27 to
60 %, depending on the diagnostic criteria applied, thera-
peutic approach and time when the assessment is made
[1–4].
Acute myocardial infarction (MI) provokes a systemic
inﬂammatory response with a release of pro-inﬂammatory
cytokines and enhanced synthesis of C-reactive protein
(CRP) [5]. The triggers of cytokine and growth factor
release in the setting of MI include mechanical deformation
of left ventricle, ischaemia with necrosis, generation of
reactive oxygen species, and cytokine self-ampliﬁcation
pathways [6]. Those mediators affect necrosis expansion
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123and scar formation as well as stimulate CRP expression [7].
An increase in CRP plasma concentration in the course of
acute MI begins in the ﬁrst hours following the onset of
symptoms, peaks approximately on day 2, and returns to its
baseline value after a few weeks [8].
An accumulating body of evidence indicates a close
relationship between increased CRP concentrations in
patients with MI and excessive mortality in the medium-
and long-term follow-up [9–13]. Additionally, evaluation
of CRP concentration in this population provides prog-
nostic information independent from the classical risk
factors and enhances the value of well-established risk
scores [14]. However, the link between CRP and structural
and functional cardiac alterations in STEMI patients war-
rants further investigation.
We therefore set out to assess the usefulness of in-hos-
pital measurement of CRP plasma concentration in
comparison to well-established clinical, biochemical and
angiographic risk factors as a marker of post-infarct LVSD
at discharge in patients with a ﬁrst ST-segment-elevation
myocardial infarction (STEMI) treated with primary per-
cutaneous coronary intervention (pPCI).
Materials and methods
Study design and patient characteristics
This study was designed as a single-center prospective
observational cohort trial in the setting of ﬁrst STEMI
treated with pPCI. Two hundred and four consecutive
patients (156 men and 48 women) meeting the study
inclusion and exclusion criteria were enrolled.
The inclusion criteria were as follows: (1) typical
stenocardial chest pain of at least 30 min duration, (2)
onset of symptoms\12 h before hospital admission and (3)
electrocardiographic features of acute STEMI (ST-segment
elevation C0.1 or C0.2 mV in at least two continuous limb
or precordial leads, respectively).
The exclusion criteria were: (1) prior coronary revas-
cularization, (2) cardiogenic shock on admission, (3) heart
failure (class III or IV according to the New York Heart
Association classiﬁcation), (4) bundle branch block, (5)
permanent atrial ﬁbrillation, (6) hemodynamically signiﬁ-
cant valvular heart disease, (7) primary cardiomyopathy,
(8) severe arterial hypertension, (9) creatinine concentration
[176.8 mmol/L, (10) the presence of features suggestive
of an active inﬂammatory or neoplastic process on
admission, and (11) therapy with steroids, immunosup-
pressive agents and non-steroidal anti-inﬂammatory drugs
(excluding low doses of aspirin).
The study endpoint was global LVSD, the echocardio-
graphic criterion for which was deﬁned based on previous
studies as left ventricular ejection fraction (LVEF) B40 %
[2, 15, 16]. The patients were divided according to the
values of LVEF at discharge into the subgroups with
(LVEF B40 %) and without (LVEF[40 %) LVSD.
Approval from the local Bioethics Committee at Col-
legium Medicum in Bydgoszcz was obtained. All patients
gave their written, voluntary, informed consent for partic-
ipation in the study.
Pharmacotherapy
At the ﬁrst contact with health care providers immediately
after the diagnosis of STEMI, all patients were pre-treated
with an intravenous bolus of unfractionated heparin (70 IU/
kg, up to 5,000 IU) and oral loading doses of clopidogrel
(600 mg) and aspirin (300 mg). At the catheterization
laboratory a second dose of unfractionated heparin was
administered intra-arterially in a weight-adjusted manner
(up to 100 IU/kg) or under activated clotting time guidance
(to the target range of 200–250 s) when abciximab was
intended. Abciximab was given at the discretion of the
invasive cardiologist. Throughout the study period clopi-
dogrel and aspirin 75 mg q.d. were continued in all
patients. Concomitant medications in the majority of
patients included perindopril and long-acting metoprolol in
doses adjusted for resting heart rate and blood pressure, and
simvastatin 40 mg q.d. (Table 1). Additionally, 17 (8.3 %)
patients were treated with spironolactone while 13 (6.4 %)
participants received non-potassium-sparing diuretics.
Coronary angiography and pPCI
Coronarography and pPCI were performed using a standard
femoral approach. The use of aspiration thrombectomy
during the intervention was left to the operator’s discretion.
Intracoronary stents were routinely implanted. Coronary
artery stenosis was measured with quantitative coronary
angiography. Epicardial coronary ﬂow was assessed
according to the Thrombolysis in Myocardial Infarction
(TIMI) score and TIMI frame count (TFC), and myocardial
perfusion according to the TIMI Myocardial Perfusion
Grade (TMPG).
Echocardiography
Transthoracic echocardiographic recordings employing the
Doppler technique were acquired before discharge using
a Philips SONOS 7500 Ultrasound System, according
to the protocol recommended by the American Society
of Echocardiography [17]. Echocardiographic recordings
were assessed ofﬂine by two independent experienced
echocardiographers blinded to the values of biomarker
measurement. Measurements are reported as the average of
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123three consecutive cardiac cycles. The echocardiographic
results obtained by echocardiographers were averaged. The
inter- and intra-observer coefﬁcients of variation for LVEF
assessed in the ﬁrst 50 patients were below 5.0 and 2.5 %,
respectively.
We assessed the sizes of the heart chambers, myocar-
dium wall thickness and the following parameters of left
ventricular systolic function: (1) LVEF measured with the
biplane method of discs in four- and two-chamber views,
and (2) wall motion score index (WMSI), derived as a sum
of all scores divided by the number of segments visualized,
implementing the 16-segment model of left ventricle seg-
mentation and assigning a score of 1, 2, 3, or 4 points for
normokinesis, hypokinesis, akinesis and dyskinesis,
respectively [18]. Left ventricular mass was calculated
according to the Devereux formula [19]. Measurements of
peak systolic mitral annular velocities were obtained for
four basal segments of the left ventricle (septal, lateral,
inferior and anterior) using pulsed tissue Doppler echo-
cardiography with the Doppler gate targeted at the junction
between the left ventricle walls and the mitral annulus in
four- and two-chamber views. The average peak systolic
mitral annular velocity (S0) and an average septal and lat-
eral peak systolic mitral annular velocity (S00) were
obtained.
Blood sampling and laboratory analyses
Peripheral venous blood samples were collected using
ethylenediaminetetraacetic acid tubes. After being centri-
fuged, the plasma was stored at -80 C until analyzed.
CRP plasma concentrations were measured with an
ultra-sensitive latex immunoassay (CRP Vario test, ana-
lyzer: ARCHITECT ci8200, Abbott) at admission, 24 h
after admission and at discharge. B-type natriuretic peptide
(BNP) plasma concentration was measured with a
chemiluminescent microparticle immunoassay (analyzer:
ARCHITECT ci8200) at admission and at discharge. The
limits of detection for CRP and BNP were 0.1 mg/L and
10 pg/L, respectively. The intra-assay coefﬁcients of vari-
ation were below 2.0 % for CRP and below 5.0 % for
BNP, while the inter-assay coefﬁcients of variation were
Table 1 Demographic and clinical characteristics of the study population
Variable Overall study
population
(n = 204)
Patients with
LVSD (n = 57)
Patients without
LVSD (n = 147)
p for comparison
between groups with
and without LVSD
Age (years) 57.0 ± 9.2 59.0 ± 8.7 56.2 ± 9.3 \0.05
Gender (male/female), n (%) 156/48 (76.5/23.5) 43/14 (75.4/24.6) 113/34 (76.9/23.1) NS
Anterior wall STEMI, n (%) 89 (43.6) 52 (91.2) 37 (25.2) \0.001
Time from onset of pain to balloon (min) 238.2 ± 151.1 233.8 ± 150.0 244.9 ± 150.8 NS
Risk factors for coronary artery disease
Body mass index (kg/m
2) 26.8 ± 3.9 27.9 ± 4.3 26.4 ± 3.6 \0.01
Hypertension, n (%) 84 (41.2) 31 (54.4) 53 (36.1) \0.02
Diabetes mellitus, n (%) 37 (18.1) 15 (26.3) 22 (15.0) NS
Current or ex-smoker, n (%) 134 (65.7) 34 (59.7) 100 (68.0) NS
LDL cholesterol (mmol/L) 3.87 ± 1.02 3.92 ± 1.09 3.85 ± 1.0 NS
HDL cholesterol (mmol/L) 1.37 ± 0.29 1.27 ± 0.26 1.38 ± 0.29 \0.05
Triglycerides (mmol/L) 1.33 ± 1.08 1.41 ± 0.86 1.30 ± 1.15 \0.05
Cardiological history
Angina proceeding to myocardial infarction, n (%) 86 (42.2 %) 26 (45.6 %) 60 (40.8 %) NS
Heart failure prior to MI (I or II class
according to the NYHA classiﬁcation), n (%)
7 (3.5) 3 (5.3) 4 (2.7) NS
Medical treatment
Long-acting metoprolol 202 (99.0 %) 56 (98.2 %) 146 (99.3 %) NS
Perindopril 200 (98.0 %) 55 (96.5 %) 145 (98.6 %) NS
Simvastatin 203 (99.5 %) 57 (100.0 %) 146 (99.3 %) NS
Spironolactone 17 (8.3 %) 10 (17.5 %) 7 (4.8 %) \0.004
Non-potassium-sparing diuretics 13 (6.4 %) 8 (14.0 %) 5 (3.4 %) \0.006
LVSD left ventricular systolic dysfunction, MI myocardial infarction, NYHA New York Heart Association, STEMI ST-segment-elevation
myocardial infarction
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123below 1.0 % for CRP and below 5.0 % for BNP,
respectively.
Statistical analysis
Due to major advances in STEMI management resulting in
improved survival and lower prevalence of post-infarct
LVSD along with reductions in mean CRP values in
STEMI patients in recent years, we decided to perform an
internal pilot study of the ﬁrst 50 patients for estimating the
ﬁnal sample size. To compensate for the potential loss of
patients due to withdrawal of consent or other reasons, we
enrolled an additional patient. LVSD was present in 15
(29.4 %) subjects. CRP concentrations in the ﬁrst 51
patients assessed for the overall population and for patients
with and without LVSD were, respectively (1) on admis-
sion 2.6 ± 2.1, 2.7 ± 1.9 and 2.6 ± 2.1 mg/L, (2) at 24 h
after admission 15.8 ± 14.1, 25.6 ± 19.0 and 11.7 ± 9.7
mg/L, and (3) at discharge 16.5 ± 16.2, 24.0 ± 19.9 and
13.4 ± 13.5 mg/L. Based on these results and assuming a
two-sided alpha value of 0.05, we calculated that enrolment
of 200 patients would provide a 99.9 and 98.9 % power to
demonstrate signiﬁcant differences in CRP concentrations
between patients with and without LVSD at 24 h after
admission and at discharge, respectively. We decided to
obtain such high power to be able to perform credible
multivariate analyses.
Continuous variables were presented as mean val-
ues ± standard deviations. The Shapiro–Wilk test was
used to demonstrate whether the investigated variables
were normally distributed. Depending on the presence or
absence of normal distribution, inter-group comparisons
were performed with Student’s t test for independent
samples or the Mann–Whitney unpaired rank sum test,
whereas Student’s t test for paired samples or the Wilcoxon
matched-paired rank sum test were applied for compari-
sons within the groups. Categorical variables were
compared using the v
2 test with Yates’ correction if
needed.
Univariate and multivariate logistic regression models
were used to identify markers of LVSD. Relations between
the investigated variables and the likelihood of LVSD were
estimated with the use of odds ratios (ORs) and their 95 %
conﬁdence intervals (95 % CIs). The optimal cut-off points
were determined using receiver operator characteristic
(ROC) curve analysis.
The impact of numerous variables on a quantitative
variable was assessed using the multiple regression model.
A two-sided difference was considered signiﬁcant at
p\0.05. The statistical analysis and sample size calcula-
tion were carried out using the Statistica 10.0 package
(StatSoft, Tulsa, OK, USA).
Results
Clinical, echocardiographic and angiographic
assessment
LVSD at discharge was present in 57 (27.9 %) patients in
our study. Patients with LVSD when compared to those
with LVEF [40 % were older, had much more frequent
anterior location of STEMI, and were more likely to be
overweight, dyslipidemic and hypertensive (Table 1).
The subgroup with LVEF B40 % had signiﬁcantly
higher diameters of left atrium and left ventricle, bigger
systolic and diastolic left ventricular volumes and greater
left ventricle mass than patients with LVEF [40 %
(Table 2). Similarly, in the former group we observed
signiﬁcantly higher values of WMSI and markedly lower
average peak systolic mitral annular velocity and average
septal and lateral peak systolic mitral annulus velocity
indicating more impaired regional and longitudinal left
ventricular systolic function.
In accordance with the dominant anterior location of
STEMI in patients with LVSD, the culprit lesion was found
much more frequently in the left descending artery in
this subgroup than in patients without LVSD (Table 2).
Furthermore, patients with LVEF B40 % at discharge
presented with considerably less favourable pre-pPCI
angiographic indices and interventional cardiologists were
more likely to administer abciximab in this population than
in patients with LVEF [40 % at discharge (Table 2).
Although in the majority of patients pPCI resulted in a
complete restoration of epicardial blood ﬂow in the infarct-
related artery, the incidence of complete reperfusion in the
area of STEMI denoted by TMPG 3 was below 50 % in
both subgroups.
Biomarkers
Patients with LVSD at discharge when compared to those
with LVEF [40 % presented with a signiﬁcantly higher
maximal concentration of troponin I, markedly ele-
vated plasma glucose on admission and noticeably
increased white blood cell count at 24 h after admission
(Table 2).
CRP plasma concentration rose steeply during the ﬁrst
24 h of hospitalization (p\0.001) and persisted elevated
at discharge, mainly in patients with LVSD (Fig. 1). As
shown in Figs. 2 and 3, the prevalence of LVSD was sig-
niﬁcantly increased across increasing tertiles of CRP
concentration, both at 24 h after admission (cut-off values
of B6.5 and [15.2 mg/L for the lower and upper tertile,
respectively) and at discharge (cut-off values of\7.1 and
[15.2 mg/L for the lower and upper tertile, respectively).
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123BNP concentration increased during hospitalization
in all patients (p\0.001). However, its markedly
higher values were observed in the group with LVEF
B40 % at both time points, allowing early identiﬁca-
tion of patients prone to developing global LVSD
(Table 2).
Table 2 Angiographic, echocardiographic and biochemical characteristics of study population
Variable Overall study
population (n = 204)
Patients with
LVSD (n = 57)
Patients without
LVSD (n = 147)
p for comparison
between groups with
and without LVSD
Angiographic indices
IRA: LAD/non-LAD, n (%) 93 (45.6)/111 (54.4) 52 (91.2)/5 (8.8) 41 (27.9)/106 (72.1) \0.001
Multivessel coronary artery disease, n (%) 123 (60.3) 38 (66.7) 85 (57.8) NS
Stenosis in IRA in QCA (%)
Before pPCI 93.9 ± 9.5 95.5 ± 9.2 93.3 ± 9.5 0.035
After pPCI 11.7 ± 10.1 10.6 ± 8.2 12.1 ± 10.7 NS
TFC in IRA (frames/s)
Before pPCI 74.6 ± 33.5 83.1 ± 29.2 71.3 ± 34.6 0.021
After pPCI 25.8 ± 17.9 28.0 ± 15.2 24.9 ± 18.9 0.017
TIMI 3 ﬂow in IRA, n (%)
Before pPCI 58 (28.4) 6 (10.5) 52 (35.4) \0.001
After pPCI 190 (93.1) 50 (87.7) 140 (95.3) NS
TMPG 3 after pPCI, n (%) 94 (46.1) 28 (49.1) 66 (44.9) NS
Patients with implanted stents, n (%) 202 (99.0) 57 (100) 145 (98.6) NS
Patients with implanted DES, n (%) 4 (2.0) 2 (3.6) 2 (1.4) NS
Abciximab use, n (%) 50 (24.5) 23 (41.1) 27 (18.6) \0.001
Echocardiographic indices
LA (mm) 39.7 ± 4.5 41.1 ± 5.3 39.1 ± 4.1 0.029
LVEDd (mm) 48.7 ± 5.5 51.4 ± 5.1 47.6 ± 5.3 \0.001
LVESd (mm) 33.8 ± 4.8 36.8 ± 5.1 32.6 ± 4.2 \0.001
LVMI (g/m
2) 115.7 ± 25.2 136.1 ± 24.7 107.8 ± 20.5 \0.001
LVEDVI (mL/m
2) 53.0 ± 12.6 60.5 ± 14.5 50.1 ± 10.5 \0.001
LVESVI (mL/m
2) 29.7 ± 9.5 38.5 ± 10.5 26.3 ± 9.5 \0.001
WMSI (points) 1.6 ± 0.2 1.8 ± 0.1 1.5 ± 0.2 \0.001
S0 (cm/s) 7.2 ± 1.4 6.1 ± 1.1 7.6 ± 1.4 \0.001
S00 (cm/s) 7.2 ± 1.5 6.1 ± 1.1 7.6 ± 1.4 \0.001
Biochemical parameters
Creatinine (lmol/L) 85.0 ± 15.7 87.6 ± 16.7 84.0 ± 15.2 NS
Admission glucose (mmol/L) 8.46 ± 3.05 9.77 ± 4.24 7.96 ± 2.26 0.002
HbA1c (%) 6.3 ± 1.1 6.6 ± 1.4 6.2 ± 1.0 NS
TnImax (ng/mL) 32.1 ± 19.6 43.4 ± 14.3 27.7 ± 19.7 \0.001
CK-MBmax (U/L) 120.5 ± 81.6 158.1 ± 86.3 105.5 ± 74.8 \0.001
Leukocyte count at admission (10
3 per lL) 11.2 ± 3.0 11.6 ± 2.8 11.1 ± 3.0 NS
Leukocyte count 24 h after admission (10
3 per lL) 10.3 ± 2.6 11.5 ± 3.0 9.9 ± 2.2 \0.001
BNP at admission (pg/mL) 87.1 ± 140.0 136.8 ± 230.4 67.9 ± 74.6 0.002
BNP at discharge (pg/mL) 205.0 ± 260.2 401.0 ± 386.0 129.0 ± 127.0 \0.001
Echocardiographic indices are derived from 2D and Doppler echocardiography and tissue Doppler echocardiography at hospital discharge
BNP B-type natriuretic peptide, CK-MBmax maximal activity of isoenzyme MB of creatine kinase, DES drug-eluting stent, IRA infarct-related
artery, LA left atrium; LAD left anterior descending artery, LVEDd left ventricular end-diastolic diameter, LVEDVI left ventricular end-diastolic
volume index, LVESd left ventricular end-systolic diameter, LVESVI left ventricular end-systolic volume index; LVMI left ventricle mass index,
LVSD left ventricular systolic dysfunction, pPCI primary percutaneous coronary intervention, TnImax maximal concentration of troponin I, TIMI
Thrombolysis in Myocardial Infarction score, TFC TIMI frame count, TMPG TIMI Myocardial Perfusion Grade, S0 average peak systolic mitral
annular velocity, S00 average septal and lateral peak systolic mitral annulus velocity, WMSI wall motion score index
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Markers of LVSD at discharge revealed by the univariate
logistic regression analysis are presented in Table 3. The
ﬁnal model of multivariate logistic regression analysis
found the anterior location of STEMI, maximal concen-
tration of troponin I and CRP plasma concentration at
discharge to be independent factors associated with early
LVSD. Surprisingly, despite a very good ability to distin-
guish between patients with and without LVSD and an
excellent discriminating value in the univariate analysis,
BNP concentration failed to be an independent marker of
LVSD in the multivariate analysis. Similarly, when
adjusted for CRP concentration the leukocyte count was no
longer associated with LVSD in the multivariate analysis.
Optimal cut-off values for the detection of LVSD
The ROC curve analysis assessing the diagnostic accuracy
for the detection of LVSD at discharge revealed optimal
cut-off values of 17.5 mg/L for CRP at discharge (sensi-
tivity 49.1 %, speciﬁcity 83.7 %, positive value for LVSD
detection 53.8 %, negative value for LVSD detection
80.9 %) and 46.3 ng/mL for maximal troponin I concen-
tration (sensitivity 80.7 %, speciﬁcity 63.9 %, positive
value for LVSD detection 46.5 %, negative value for
LVSD detection 89.5 %). Areas under the ROC curves for
CRP at discharge and the maximal troponin I concentration
were 0.695 (95 % CI 0.627–0.757) and 0.779 (95 % CI
0.716–0.834), respectively. Comparison of the ROC curves
for both biomarkers in terms of their diagnostic accuracy
demonstrated the superiority of the maximal troponin I
concentration over CRP value at discharge of a borderline
signiﬁcance (p = 0.06).
Determinants of CRP concentration
We applied the multiple regression model to determine
which of the demographic, clinical, angiographic and bio-
chemical parameters listed in Tables 1 and 2 affect CRP
concentration at discharge. Increased BNP values at dis-
charge, high maximal concentration of troponin I and
elderly age were independently associated with elevated
CRP concentration at discharge (Table 4).
Discussion
The main ﬁnding of our study is a clear relationship
between in-hospital CRP plasma concentrations and the
development of early post-infarct LVSD in patients
Fig. 1 C-reactive protein plasma concentrations as mean values and
standard deviations on admission, 24 h after admission and at hospital
discharge in patients with and without early post-infarct left ventricular
systolic dysfunction. LVEF left ventricular ejection fraction
Fig. 2 Incidence of global left ventricular systolic dysfunction at
hospital discharge according to tertiles of C-reactive protein plasma
concentration 24 h after admission. CRP C-reactive protein, LVEF
left ventricular ejection fraction
Fig. 3 Incidence of global left ventricular systolic dysfunction at
hospital discharge according to tertiles of C-reactive protein plasma
concentration at discharge. CRP C-reactive protein, LVEF left
ventricular ejection fraction
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123undergoing pPCI for a ﬁrst STEMI. In the homogeneous
population treated in line with contemporary standards,
CRP maintained its discriminating value for early post-
infarct LVSD detection, even when adjusted for well-
established clinical, biochemical and angiographic risk
factors. Of interest, CRP concentration at discharge iden-
tiﬁed patients with early post-infarct LVSD better than
leukocyte count and BNP concentration. When CRP value
at discharge was incorporated into the multivariable model,
both leukocyte count and BNP concentration lost their
discriminating values.
The rapid rise in CRP concentration within 24 h of
symptom onset persisting until discharge reﬂects the
severity of the inﬂammatory reaction within the infarcted
area. We found maximal concentration of troponin I, BNP
value at discharge and patient’s age to be independent
determinants of the magnitude of the inﬂammatory
response assessed by CRP concentration at discharge.
We selected CRP as a sensitive, well-standardized bio-
marker with proven value in terms of clinical risk
stratiﬁcation in cardiovascular medicine. Increased CRP
concentrations were linked with an excess risk of death,
Table 3 Markers of early left
ventricular systolic dysfunction
in univariate and multivariate
analyses
Univariate analysis shows
demographic, clinical,
angiographic and biochemical
parameters from Tables 1 and 2
with a p value B0.1 as well as
CRP and leukocyte count
independently of a p value
BNP B-type natriuretic peptide,
CI conﬁdence interval,
CK-MBmax maximal activity of
isoenzyme MB of creatine
kinase, CRP C-reactive protein,
MI myocardial infarction,
NYHA New York Heart
Association, OR odds ratio,
STEMI ST-segment-elevation
myocardial infarction,
TnImax maximal concentration
of troponin I
OR 95 % CI p
Univariate analysis
Anterior vs. non-anterior wall STEMI 30.92 11.41–83.75 \0.0001
Heart failure prior to MI (I or II class according
to the NYHA classiﬁcation)
7.52 3.00–18.83 \0.0002
Body mass index (for a 10 kg/m
2 increase) 2.76 1.22–6.23 \0.02
Hypertension 2.11 1.13–3.95 \0.02
Diabetes mellitus 2.03 0.96–4.29 0.066
BNP at discharge (for a 100 pg/mL increase) 1.89 1.48–2.43 \0.0001
TnImax (for a 10 ng/mL increase) 1.67 1.35–2.06 \0.0001
BNP at admission (for a 100 pg/mL increase) 1.61 1.14–2.28 \0.01
CRP 24 h after admission (for a 10 mg/L increase) 1.60 1.27–2.00 \0.0001
CRP at discharge (for a 10 mg/L increase) 1.55 1.24–1.93 \0.0002
Age (for a 10-year increase) 1.38 0.99–1.94 0.056
CRP at admission (for a 10 mg/L increase) 1.37 0.27–7.03 0.70
Leukocyte count 24 h after admission
(for a 10
3 per lL increase)
1.30 1.14–1.48 \0.002
HbA1c (for a 1 % increase) 1.29 1.00–1.66 \0.05
Admission glycaemia (for a 1 mmol/L increase) 1.21 1.08–1.35 \0.001
CK-MBmax (for a 10 U/L increase) 1.08 1.04–1.13 \0.0002
Leukocyte count at admission (for a
10
3 per lL increase)
1.06 0.96–1.18 0.25
Multivariate analysis
Anterior vs. non-anterior wall STEMI 26.67 9.42–75.52 \0.001
TnImax (for a 10 ng/mL increase) 1.39 1.10–1.77 \0.007
CRP at discharge (for a 10 mg/L increase) 1.38 1.01–1.87 \0.04
Table 4 Impact of demographic, clinical, angiographic and biochemical variables from Tables 1 and 2 on CRP concentration at discharge in the
multiple regression model
Beta
coefﬁcient
Beta coefﬁcient
standard error
Direction
component beta
Direction component
beta standard error
p
Model characteristics: R = 0.50; R
2 = 0.25; p\0.00001
Intercept -0.80 0.61
Age (for a 10-year increase) 0.15 0.06 0.24 0.10 \0.02
TnImax (for a 10 ng/mL increase) 0.21 0.07 0.15 0.05 \0.002
BNP at discharge (for a 100 pg/mL increase) 0.35 0.07 0.20 0.04 \0.00001
CRP C-reactive protein, TnImax maximal concentration of troponin I
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123heart failure, cardiac rapture, ventricular aneurysmal for-
mation, and thrombus formation in MI survivors [9–13, 20,
21]. Incorporation of CRP into the Global Registry of
Acute Coronary Events risk score further improved its
predictive power [14]. Therefore, combining these data
with our results, we and other authors believe that CRP
might be a simple and reliable marker for the magnitude of
the inﬂammatory response to myocardial necrosis, pro-
viding prognostic information in STEMI patients [10, 22].
To the best of our knowledge, this is the ﬁrst study
linking CRP concentration and post-infarct LVSD con-
ducted exclusively in a STEMI population, in a subset of
patients with severely deteriorated epicardial blood ﬂow
and a large area of infarcted myocardium. Moreover, we
applied strict inclusion criteria and numerous exclusion
criteria to eliminate many of the potential confounders in
our study. Almost three-quarters of our patients had an
impaired TIMI ﬂow on the initial angiogram while the
median maximal concentration of troponin I in the study
participants was 100-fold higher than the detection limit for
MI in our laboratory. Previous studies in this ﬁeld mostly
recruited patients with a broad spectrum of acute coronary
syndromes [23–25]. This fact seems to be of paramount
importance when considering different mechanisms
responsible for CRP synthesis as well as dissimilar mag-
nitudes of CRP release in MI versus unstable angina [22,
26]. In stable and unstable coronary artery disease, elevated
CRP reﬂects inﬂammation in the vascular bed or vulnera-
bility of unstable plaques in contrast to MI, where the
inﬂammatory response to myocardial necrosis dominates.
As far as we know a study conducted by Aggelopoulos
et al. [23] is the only one to date investigating the rela-
tionship between CRP concentration and the presence of
LVSD in patients treated for acute coronary syndromes.
Other studies [24, 25, 27] in this ﬁeld assessed LVEF as a
continuous variable. Aggelopoulos et al. [23] showed that
an increase in CRP plasma concentration during 12 h after
admission as high as 10 mg/L was an independent pre-
dictor of a 6 % augmentation of risk for LVSD at
discharge. However, the results may be at least partially
ﬂawed by important limitations such as retrospective case–
control design, history of coronary artery disease in almost
half of the study participants, inclusion of patients with
unstable angina, exclusion of patients with LVEF between
40 and 50 % from the analysis and application of low-
sensitivity CRP assay.
Studies linking CRP concentrations and LVEF in MI
survivors gave conﬂicting results [8, 25, 28]. Ørn et al.
demonstrated that early measurement of CRP (viz. at
2 days and 1 week) signiﬁcantly predicted LVEF assessed
by cardiac magnetic resonance after 2 months in a small
but well-designed study of STEMI patients [28]. Similarly,
Uehara et al. [8] found a signiﬁcant inverse correlation
between the peak of in-hospital CRP concentration and
LVEF at 1 month after STEMI. It is likely that various
confounders present in many of the studies addressing this
issue might lead to unreliable conclusions. For example,
heterogeneity of the investigated population, with a sub-
stantial proportion of unstable angina patients, might have
been the reason for the lack of correlation between CRP
concentration and LVEF in the study by Brunetti et al. [25].
Furthermore, the timing of CRP assessment in the course of
MI seems to be crucial for its diagnostic value. In our
study, while absent on admission (with 4 h mean delay
between symptom onset and admission), signiﬁcantly
higher CRP concentrations were present 24 h after
admission and at discharge in patients with early LVSD.
Corresponding to our results, Arruda-Olson et al. [24]
observed comparable values of LVEF and WMSI in tertiles
of CRP evaluated at a median of 6.1 h after symptom
onset. On the other hand, Suleiman et al., who measured
CRP 12–24 h after symptom onset, found inverse relations
between CRP concentration and both LVEF and WMSI
values in patients with acute MI [10].
Finally, it remains an unsolved issue whether CRP
directly contributes to post-infarct LVSD and may be a
potential therapeutic target, or if it just reﬂects an increased
risk for unfavourable outcome as a bystander marker [29,
30]. A large body of basic scientiﬁc evidence suggests that
CRP possesses both pronecrotic and proatherogenic fea-
tures. Firstly, CRP binds to phosphocholine groups of
necrotic myocardial cell membranes, leading to comple-
ment activation and thus promoting further inﬂammatory
response, injury of myocardial cells and expansion of
necrosis [31, 32]. Secondly, elevated endogenous CRP was
associated with an increase in ischemia/reperfusion injury
in a rabbit model [33]. Thirdly, increased C-reactive pro-
tein expression exacerbated LVSD and remodeling after
MI in a mouse model [34]. This deleterious effect of CRP
on post-MI left ventricular remodeling was related to
increased apoptotic rates, macrophage inﬁltration, mono-
cyte chemotactic protein-1 expression and matrix
metalloproteinase-9 activity in the border zone. Addition-
ally, CRP reduces bioavailability of nitric oxide, which in
turn suppresses angiogenesis [35]. CRP also inhibits
endothelial progenitor cell differentiation, function and
survival [36].
Limitations of the study
Major limitations of our study include short-term follow-up
and lack of concomitant assessment of cytokines and
growth factors. Furthermore, due to early achievement of
reperfusion, our patients had relatively well-preserved left
ventricular systolic function. Additionally, we did not
account in our calculations for diurnal and seasonal
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123variations in CRP concentration. Despite encouraging
results obtained in our study, further efforts are warranted
to conﬁrm their clinical signiﬁcance and to fully explain
the mechanisms through which augmentation of the
inﬂammatory process contributes to the occurrence of
LVSD and subsequently to the development of heart failure
following a STEMI.
Conclusions
The measurement of CRP plasma concentration at dis-
charge may be useful as a marker of early LVSD in patients
after a ﬁrst STEMI.
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